BRD8

Across TCGA pan-cancer cohorts, BRD8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BRD8 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher BRD8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BRD8 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, HNSC, and LSCC are the cancer types where BRD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.595	0.281	<.001	17	view →
HNSC	DFS	Quartile	IV	0.506	0.809	.007	8	view →
LSCC	DFS	Median	All	0.821	0.613	.007	8	view →
OV	DFS	Tertile	All	1.000	0.682	.025	4	view →
CCRCC	OS	Median	II,III,IV	0.867	1.000	.032	1	view →
PDAC	DFS	Median	All	0.882	0.716	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BRD8–GBM (OS)

Open the GBM breakdown →